Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

2023· article· en· 403 citations· W4362735831 on OpenAlex· 10.1002/cpt.2903

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

Full frame distilled prediction

Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

Candidate categories: Meta-epidemiology (narrow), Research integrity
Consensus categories: Research integrity
Domain: Candidate signal: noneConsensus signal: none
Study design: Candidate signal: Not applicableConsensus signal: Not applicable
Genre: Candidate signal: EmpiricalConsensus signal: Empirical
Teacher disagreement score: 0.486
Threshold uncertainty score: 1.000
Validation status: machine_predicted_unvalidated · codex-gemma-dda1882f352a

Codex and Gemma teacher scores by category

Category	Codex	Gemma
Metaresearch	0.008	0.000
Meta-epidemiology (narrow)	0.001	0.001
Meta-epidemiology (broad)	0.002	0.001
Bibliometrics	0.000	0.001
Science and technology studies	0.001	0.002
Scholarly communication	0.000	0.000
Open science	0.001	0.001
Research integrity	0.001	0.002
Insufficient payload (model declined to judge)	0.001	0.000

Machine scores (provisional)

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Opus teacher head0.261

GPT teacher head0.571

Teacher spread: 0.310 · how far apart the two teachers sit on this one work
Validation status: score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI-like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin-2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue: Clinical Pharmacology & Therapeutics
Topic: Pharmacogenetics and Drug Metabolism
Field: Pharmacology, Toxicology and Pharmaceutics
Canadian institutions: University of TorontoCentre for Addiction and Mental HealthAlberta Children's HospitalUniversity of Calgary
Funders: Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Center for Advancing Translational SciencesNational Institute of Child Health and Human DevelopmentNational Institute of General Medical SciencesNational Human Genome Research InstituteNational Institutes of HealthPatient-Centered Outcomes Research Institute
Keywords: CYP2C19PharmacogeneticsSerotonin reuptake inhibitorMedicineCYP2B6CYP2D6GuidelineInternal medicineGenotypeSerotoninCYP3A4BiologyGeneticsCytochrome P450
Has abstract in OpenAlex: yes
API: /api/v1/works/W4362735831